Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in obese adults with type 1 diabetes using hybrid closed-loop system
NCT05537233Phase 2Completed
- Start
- Apr 2023
- Primary completion
- Aug 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) and obesity comparing Semaglutide Arm with Placebo Arm (2 arms). Primary endpoint: Proportion of Adults With T1D Achieving Composite Outcome (TIR > 70%, TBR < 4%, and Weight Loss >= 5%) at 26 weeks. Started Apr 2023; status: completed.
02
Drugs
03
Conditions
type 1 diabetes mellitus (T1D)obesity
Beyond the preview
Go deeper on NCT05537233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05537233.